# ScoreItem: Albumina

**ID:** `c77cedd3-2800-7633-b793-4f5c9ab56b59`
**FullName:** Albumina (Exames - Laboratoriais)
**Unit:** g/dL

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 20 artigos
- Avg Similarity: 0.574

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7633-b793-4f5c9ab56b59`.**

```json
{
  "score_item_id": "c77cedd3-2800-7633-b793-4f5c9ab56b59",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Albumina (Exames - Laboratoriais)
**Unidade:** g/dL

**30 chunks de 20 artigos (avg similarity: 0.574)**

### Chunk 1/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.622

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 2/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.598

hohavemetabolicdisordersandareonaverylow‚Äìproteindiet,acystatinC‚Äìbasedequationislikelymoreappropriate.1.3EvaluationofalbuminuriaAlbuminuriareferstoabnormallossofalbuminintheurine(urineACR$30mg/gor$3mg/mmol).Albuminisonetypeofplasmaproteinfoundintheurineinnormalsubjectsand
inlargerquantityinpeoplewithkidneydisease.IntheKDIGO
2012ClinicalPracticeGuidelinefortheEvaluationand
ManagementofChronicKidneyDisease,1clinicalterminologywaschangedtofocusonalbuminuriaratherthanproteinuria
asalbuministheprincipalcomponentofurinaryproteininmostkidneydiseases.Epidemiologicdatademonstrateastrongrelationshipbetweenthequantityofurinealbuminwithboth
kidneyandCVDriskandobservedCVDevenatverylow
levels,andassaystomeasurealbuminaremorepreciseand
sensitivethanassaystomeasureurineprotein.Wereferto
albuminuriaorurinealbuminwhendiscussinggeneral
conceptsandwillrefereithertototalprotein,albumin,orother
specicproteinswhendiscussingthatparameterspecically.1.3.1GuidanceforphysiciansandotherhealthcareprovidersPrac

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.596

chmannLM.Movingtowardstandardizationofurinealbuminmeasurements.EJIFCC.2017;28:258‚Äì267.314.NationalInstituteofStandardsandTechnology.CerticationofStandardReferenceMaterial2925RecombinantHumanSerumAlbuminSolution(PrimaryReferenceCalibratorforUrineAlbumin)(Frozen).U.S.DepartmentofCommerce,NIST;2020.315.CarterJL,ParkerCT,StevensPE,etal.Biologicalvariationofplasmaand
urinarymarkersofacutekidneyinjuryinpatientswithchronickidneydisease.ClinChem.2016;62:876‚Äì883.316.NationalInstituteforHealthandCareExcellence.Point-of-carecreatininedevicestoassesskidneyfunctionbeforeCTimagingwithintravenous
contrast.NICEGuideline[NG37].NICE;2019.317.BatteA,MurphyKJ,NamazziR,etal.Evaluatingkidneyfunctionusingapoint-of-carecreatininetestinUgandanchildrenwithseveremalaria:aprospectivecohortstudy.BMCNephrol.2021;22:369.318.McTaggartMP,NewallRG,HirstJA,etal.Diagnosticaccuracyofpoint-of-
caretestsfordetectingalbuminuria:asystematicreviewandmeta-analysis.AnnInternMed.2014;160:550‚Äì557.319.AbitbolC,ZillerueloG,F

---

### Chunk 4/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.589

olicitar e registrar par√¢metros essenciais (PCR-us, VHS); calcular √≠ndices estim√°veis (HGI, TAIG); considerar complementares (TNF-Œ±, IL-6, GPx, MDA, antioxidantes totais).
- [ ] 11. Monitorar trimestralmente HbA1c, glicemia de jejum e HGI; estabelecer metas individuais (ex.: reduzir de 6,1 para ~5,5; longo prazo ~5,3).
- [ ] 12. Calcular TG/HDL e integrar com lipidograma/SREBP1c/2; evitar combina√ß√£o de gordura saturada com a√ß√∫car e excesso de saturadas em m√∫ltiplas refei√ß√µes.
- [ ] 13. Avaliar ferro, ferritina, transferrina e satura√ß√£o (20‚Äì50%; evitar <20%); interpretar com hepcidina/SREBP1c e quadro inflamat√≥rio.
- [ ] 14. Medir TNF-Œ± (<8,1) e IL-6 (<3,4) para acompanhar atividade inflamat√≥ria; relacionar com obesidade inflamada.
- [ ] 15. Calcular HOMA-Œ≤ (167‚Äì175) e HOMA-IR (<2,15); buscar glicemia 60‚Äì90 e insulina ~6‚Äì7.
- [ ] 16. Monitorar homociste√≠na (<7,9) e PCR; usar PCR-us; documentar crises (PCR >1.000) e conduzir manejo apropriado.
- [ ] 17.

---

### Chunk 5/30
**Article:** Aula 01 Guilherme Sorrentino - Cirurgia e Medicina Funcional Integrativa (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.588

tineira: quedas em B6, B9, B12 e beta√≠na prejudicam metila√ß√£o, elevando homociste√≠na (objetivo: valores abaixo de 10).

------------
## Avalia√ß√£o da Fun√ß√£o Org√¢nica e do Perfil Inflamat√≥rio Sist√™mico

A inflama√ß√£o sist√™mica do contexto cir√∫rgico impacta diversos sistemas. Renalmente, h√° maior demanda funcional, redu√ß√£o de eritropoetina e altera√ß√µes que, junto ao aumento de hepsidina hep√°tica, prejudicam absor√ß√£o e uso do ferro, promovendo reten√ß√£o em macr√≥fagos e ferritina. O f√≠gado √© descrito como maestro metab√≥lico: conduz gliconeog√™nese, produz prote√≠nas de fase aguda, sustenta detoxifica√ß√£o e gest√£o energ√©tica. Observa-se, na pr√°tica atual, TGO/TGP frequentemente entre 35, 40, 45, 60, indicativos de sobrecarga hep√°tica em muitos pacientes por dieta, infec√ß√µes ou inflama√ß√£o cr√¥nica‚Äîda√≠ a necessidade de aproximar o f√≠gado da homeostase antes de operar.

---

### Chunk 6/30
**Article:** Serum sodium within the normal range and its U-shaped relationship with biological aging in U.S. adults (2026)
**Journal:** Revista n√£o identificada
**Section:** methods | **Similarity:** 0.585

. 
Nutrients
. (2018) 10:1928. doi: 
10.3390/nu10121928
 16. Clark VL, Kruse JA. Clinical methods: the history, physical, and laboratory examinations. 
JAMA J AmMed Assoc
. (1990) 264:2808. doi: 
10.1001/jama.1990.03450210108045
 17. Walker HK. e Origins of the History and Physical Examination. In: Walker HK, 
Hall WD, Hurst JW, editors. Clinical Methods: e History, Physical, and Laboratory 
Examinations. 3rd edition. Boston: Butterworths (1990) 878¬ñ883.
 18. Popowski LA, Oppliger RA, Patrick Lambert G, Johnson RF, Kim Johnson A, 
Gisolf CV. Blood and urinary measures of hydration status during progressive acute 
dehydration. 
Med Sci Sports Exerc
. (2001) 33:747¬ñ53. doi: 
10.1097/00005768-
 
200105000-00011
 19. Stookey JD, Kavouras SA, Suh H, Lang F. Underhydration is associated with 
obesity, chronic diseases, and death within 3 to 6 years in the U.S. population aged 51¬ñ70 
years. 
Nutrients
. (2020) 12:905. doi: 
10.3390/nu12040905
 20.

---

### Chunk 7/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.585

60 e 90
- [ ] Manter a insulina, o mais baixo poss√≠vel, 6, 7, estourando 8
- [ ] Avaliar a homociste√≠na, pois √© um marcador inflamat√≥rio importante
- [ ] Usar a prote√≠na C-reativa, associado com os n√≠veis de homociste√≠na
- [ ] Verificar os par√¢metros essenciais na avalia√ß√£o inflamat√≥ria
- [ ] Estimar o √≠ndice de glica√ß√£o e o √≠ndice TAIG, baseado nos resultados essenciais
- [ ] Complementar a avalia√ß√£o com TNF-alfa, IL-6, glutationa e malon de alde√≠do
### Tarefas para @
- [ ] Usar um concentrado de C8 ou um mix de C8 e C10, para estimular mais ainda o CP3 e as UCPs (prote√≠nas desacopladoras), diminuir a produ√ß√£o de esp√©cie reativa de oxig√™nio e aumentar a oxida√ß√£o de gordura @
- [ ] Incluir mioinositol, trans-resveratrol e epigalocatequina galato na formula√ß√£o, para diminuir os compostos de glica√ß√£o avan√ßada e a hemoglobina glicada @
- [ ] Fazer uma boa distribui√ß√£o de gordura e trabalhar os √°cidos graxos de cadeia curta, para obter o melhor benef√≠cio p

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.583

 52.361.OlivariusND,MogensenCE.Danishgeneralpractitioners‚Äôestimationofurinaryalbuminconcentrationinthedetectionofproteinuriaand
microalbuminuria.BrJGenPract.1995;45:71‚Äì73.362.OstaV,NatoliV,Di√©guezS.[Evaluationoftworapidtestsforthe
determinationofmicroalbuminuriaandtheurinaryalbumin/creatinine
ratio].AnPediatr(Barc).2003;59:131‚Äì137[inSpanish].363.OyaertM,DelangheJR.Semiquantitative,fullyautomatedurineteststrip
analysis.JClinLabAnal.2019;33:e22870.364.ParkerJL,KirmizS,NoyesSL,etal.Reliabilityofurinalysisfor
identicationofproteinuriaisreducedinthepresenceofotherabnormalitiesincludinghighspecicgravityandhematuria.UrolOncol.2020;38:853.e859‚Äì853.e915.365.ParsonsM,NewmanDJ,PugiaM,etal.Performanceofareagentstrip
deviceforquantitationoftheurinealbumin:creatinineratioinapoint
ofcaresetting.ClinNephrol.1999;51:220‚Äì227.366.ParsonsMP,NewmanDJ,NewallRG,etal.Validationofapoint-of-care
assayfortheurinaryalbumin:creatinineratio.ClinChem.1999;45:414‚Äì417.367.PendersJ,FiersT,DelangheJR.Quan

---

### Chunk 9/30
**Article:** Modula√ß√£o Intestinal II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.582

homociste√≠na, prote√≠na C-reativa.
    - **Inflama√ß√£o intestinal:** Calprotectina fecal.
    - **Risco cardiovascular:** TMAO s√©rico (em pacientes com resist√™ncia √† insulina).
    - **Sa√∫de geral:** N√≠veis de vitamina B12, cuja absor√ß√£o depende de um pH g√°strico adequado.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Ao solicitar o exame de calprotectina fecal, justificar como "suspeita de doen√ßa inflamat√≥ria intestinal" para aumentar a chance de aprova√ß√£o pelo plano de sa√∫de.
- [ ] 2. Orientar pacientes adultos a coletar a calprotectina fecal em um dia de rotina alimentar normal (ex: quarta-feira), evitando per√≠odos p√≥s-excessos para n√£o gerar falsos positivos.
- [ ] 3. Considerar a dosagem de elastase fecal para avaliar a fun√ß√£o ex√≥crina do p√¢ncreas antes de prescrever enzimas digestivas.
- [ ] 4. Monitorar marcadores de inflama√ß√£o de baixo grau, como resist√™ncia √† insulina (HOMA-IR), homociste√≠na e prote√≠na C-reativa.

---

### Chunk 10/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.581

9.1%)Hematologicdisorders14(48.3%)15(51.7%)29(6.7%)Livercirrhosis5(2.3%)16(7.4%)21(4.9%)Diabetes33(15.3%)25(11.6%)58(13.5%)CHF11(5.1%)10(4.7%)21(4.9%)ESRD2(0.9%)3(1.4%)5(1.2%)Hepaticdecompensation6(2.8%)7(3.3%)13(3.0%)Infection23(10.7%)42(19.5%)65(15.1%)Hypotension53(24.7%)61(28.4%)114(26.5%)AdmissionatICU54(25.1%)58(27.0%)112(26.0%)InitialvaluesAST,U/L527.0(477.0‚Äì579.0)983.0(775.0‚Äì1473.0)657.0(527.0‚Äì984.3)ALT,U/L141.0(101.0‚Äì219.0)340.0(189.0‚Äì599.0)207.5(126.8‚Äì401.8)Albumin,g/dL3.5(2.9‚Äì4.0)3.6(3.0‚Äì4.1)3.5(3.0‚Äì4.0)Bilirubin,mg/dL1.06(0.72‚Äì1.62)1.02(0.73‚Äì1.62)1.03(0.73‚Äì1.62)ALP,U/L73.0(58.0‚Äì97.0)74.0(57.0‚Äì103.0)73.0(58.0‚Äì100.0)LDH,U/L910.0(495.8‚Äì1197.0)1676.0(973.0‚Äì2700.0)1148.0(716.5‚Äì1951.0)CK,U/L4294.0(3276.0‚Äì14,503.0)9250.0(3301.5‚Äì45,757.0)5646.0(3293.8‚Äì25,000.0)Creatinine,mg/dL0.94(0.70‚Äì1.47)1.20(0.85‚Äì1.91)1.05(0.76‚Äì1.63)PT-INR1.05(0.99‚Äì1.28)1.17(1.02‚Äì1.64)1.11(1.00‚Äì1.38)Peakvalues168.0(111.0‚Äì310.0)462.0(250.0‚Äì927.0)264.0(147.

---

### Chunk 11/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** discussion | **Similarity:** 0.578

Clinical and Experimental Nephrology (2025) 29:249‚Äì258 https://doi.org/10.1007/s10157-024-02606-3
INVITED REVIEW ARTICLE
Treatment ofhyponatremia: comprehension andbest clinical practiceHirofumiSumi1,2¬∑ NaotoTominaga1,2 
¬∑ YoshiroFujita3¬∑ JosephG.Verbalis4¬∑ the Electrolyte Winter Seminar Collaborative GroupReceived: 8 July 2024 / Accepted: 29 November 2024 / Published online: 23 January 2025 ¬© The Author(s) 2025AbstractThis review article series on water and electrolyte disorders is based on the ¬ëElectrolyte Winter Seminar¬í held annually for young nephrologists in Japan. The seminar features dynamic case-based discussions, some of which are included as self-assessment questions in this series. The second article in this series focuses on treatment of hyponatremia, a common water and electrolyte disorder frequently encountered in clinical practice.

---

### Chunk 12/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** methods | **Similarity:** 0.577

nsPediatricconsiderations.PracticePoint1.2.4.3:EstimateGFRinchildrenusingvalidatedequationsthathavebeendevelopedorvalidatedincomparablepopulations.1.3Evaluationofalbuminuria1.3.1GuidanceforphysiciansandotherhealthcareprovidersPracticePoint1.3.1.1:Usethefollowingmeasurementsforinitialtestingofalbuminuria(indescendingorderofpref-erence).Inallcases,arstvoidinthemorningmidstreamsampleispreferredinadultsandchildren.(i)urineACR,or(ii)reagentstripurinalysisforalbuminandACRwithautomatedreading.Ifmeasuringurineprotein,usethefollowingmeasurements:(i)urineprotein-to-creatinineratio(PCR),(ii)reagentstripurinalysisfortotalproteinwithautomatedreading,or(iii)reagentstripurinalysisfortotalproteinwithmanualreading.PracticePoint1.3.1.2:Usemoreaccuratemethodswhenalbuminuriaisdetectedusinglessaccuratemethods.Conrmreagentstrippositivealbuminuriaand/orproteinuriabyquantitativelaboratorymea-surementandexpressasaratiotourinecreatininewhereverpossible(i.e.,quantifytheACRorPCRifinitialsemiquantitativetestsar

---

### Chunk 13/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.574

with and 
without hyperbilirubinemia. Dig Dis Sci 2008;53:799-
802.163. Lazo M, Selvin E, Clark JM. Brief communication: 
clinical implications of short-term variability in liver 
function test results. Ann Intern Med 2008;148:348-52.164. Schmidt E, Schmidt FW, Chemnitz G, Kubale R, 
Lobers J. The Szasz-ratio (CK/GOT) as example for the 
diagnostic significance of enzyme ratios in serum. Klin 
Wochenschr 1980;58:709-18.165. Dufour DR. Is it necessary to order aspartate 
aminotransferase with alanine aminotransferase 
in clinical practice? Author‚Äôs Reply. Clin Chem 
2001;47:1134-5.

---

### Chunk 14/30
**Article:** Dieta Cetog√™nica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.573

sa magra.
**Operacionaliza√ß√£o e fisiologia: hidrata√ß√£o, eletr√≥litos, glicose, glicog√™nio e m√©tricas (GKI) reduzem sintomas iniciais e orientam terapia.**
- Fase inicial: mobiliza√ß√£o de ~500 g de glicog√™nio (100 g f√≠gado, 400 g m√∫sculo) libera ~1 kg de √°gua (2 g √°gua por 1 g glicog√™nio), explicando ‚Äúperda de √°gua‚Äù na primeira semana.
- Hidrata√ß√£o/eletr√≥litos: ~2 litros de l√≠quidos/dia; 1 colher de ch√° de sal seguida de √°gua melhora sintomas em ~15 minutos; considerar sensibilidade ao sal (10%‚Äì20% dos hipertensos podem piorar).
- Glicemia: dieta normal 80‚Äì120 mg/dL; cetog√™nica 65‚Äì80 mg/dL; jejum em gestantes ~60 mg/dL; <70 mg/dL pode ser perigoso com insulina; extremos incluem 600 mg/dL em DT1 sem insulina e >300 mg/dL na cetoacidose; em jejum prolongado, 30 mg/dL pode ser tolerado quando h√° cetonas.

---

### Chunk 15/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.573

S,CarlinJB,etal.Albuminuria:populationepidemiology
andconcordanceinAustralianchildrenaged11‚Äì12yearsandtheirparents.BMJOpen.2019;9:75‚Äì84.308.RademacherER,SinaikoAR.Albuminuriainchildren.CurrOpinNephrolHypertens.2009;18:246‚Äì251.309.TsiousC,MazarakiA,DimitriadisK,etal.Microalbuminuriainthepaediatricage:currentknowledgeandemergingquestions.ActaPaediatr.2011;100:1180‚Äì1184.310.EmmaF,GoldsteinS,BaggaA,etal.PediatricNephrology.8thed.Springer;2022.311.BrinkmanJW,deZeeuwD,DukerJJ,etal.Falselylowurinaryalbuminconcentrationsafterprolongedfrozenstorageofurinesamples.ClinChem.2005;51:2181‚Äì2183.312.SacksDB,ArnoldM,BakrisGL,etal.Executivesummary:guidelinesand
recommendationsforlaboratoryanalysisinthediagnosisandmanagementofdiabetesmellitus.ClinChem.2011;57:793‚Äì798.313.SeegmillerJC,MillerWG,BachmannLM.Movingtowardstandardizationofurinealbuminmeasurements.EJIFCC.2017;28:258‚Äì267.314.NationalInstituteofStandardsandTechnology.CerticationofStandardReferenceMaterial2925RecombinantHumanSerumA

---

### Chunk 16/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.572

.Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria:a
systematicreviewandmeta-analysis.AnnIntMed.2014;160:550‚Äì557.318SoFtablesSupplementaryTableS5SearchdateJuly2022
Citationsscreened/includedstudies2184/65
SupplementaryFigureS5Chapter2RiskassessmentinpeoplewithCKDClinicalquestionArekidneyfailurepredictionequationsgoodpredictorsofprogression,kidneyfailure,orend-stagerenaldisease?PopulationAdults,children,andyoungpeoplewithCKDG1-G5PredictorKidneyfailureriskequations(e.g.,Tangriequation[KidneyFailureRiskEquation])OutcomesPrognosticperformance:Calibration(goodnessofmeasures,e.g.,R2,Brierscore,andHosmer-Lemeshowtest)Discrimination(e.g.,sensitivity/specicity;areaunderthecurve[AUC]fromreceiveroperatingcharacteristic[ROC]andareaunderthereceiveroperatingcharacteristiccurve[AUROC];C-statistic)StudydesignSystematicreview
ExistingsystematicreviewNationalInstituteforHealthandCareExcellence.Evidencereviewforthebestcombinationofmeasurestoidentifyincreasedriskofprogressioninadults,childr

---

### Chunk 17/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.568

Lp(a), APO-B/APO-A, NO) para preven√ß√£o e tratamento da DCV.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Solicitar avalia√ß√£o do √≠ndice de √¥mega 3 e da raz√£o √¥mega 3:√¥mega 6; ajustar suplementa√ß√£o de √¥mega 3 conforme resultados.
- [ ] 2. Dosar vitamina D (25(OH)D) e PTH; estabelecer metas de 80 ng/mL para cardiopatas/hipertensos e considerar >100 ng/mL para autoimunes, com monitoriza√ß√£o de seguran√ßa.
- [ ] 3. Aplicar protocolo de curva de glicose e insulina (jejum, 30, 60, 90, 120 min) para detectar hiperinsulinemia oculta e resist√™ncia √† insulina.
- [ ] 4. Introduzir metformina em casos de resist√™ncia √† insulina, juntamente com plano nutricional coordenado com nutricionista.
- [ ] 5. Avaliar homociste√≠na e intervir com vitaminas B9, B12 e B6 em casos de eleva√ß√£o, considerando polimorfismos de metila√ß√£o.
- [ ] 6.

---

### Chunk 18/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.566

eneral,all3devicesdemonstratedacceptableaccuracyatlowerlevelsofeGFR(<30ml/minper1.73m2).316Resultsshowedthati-STATandABLdevicesmayhavehigherprobabilitiesofcorrectlyclassifyingpeopleinthesameeGFRcategoriesasthelaboratoryreferencethan
StatSensordevices.Foralbumin,theERTidentiedasystematicreviewpub-lishedin2014,byMcTaggartetal.,318thatevaluatedthediagnosticaccuracyofquantitativeandsemiquantitativeproteinoralbuminurinedipsticktestscomparedwithlaboratory-basedtestsamongpeoplewithsuspectedor
diagnosedCKD.TheERTincludedrelevantstudiesfrom
thisreviewandconductedanupdate.Sixty-vestudies(in66articles)319‚Äì344,345‚Äì368,369‚Äì384eval-uatedtheaccuracyofquantitativeandsemiquantitativepro-
teinoralbumindipsticktestsinageneralpopulationnoton
chapter1www.kidney-international.orgS194KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

KRTorreceivingend-of-lifecare.Studiesaddressedthefollowingcriticaloutcomes:measurementbias(n¬º1),analyticalvariability(n¬º5),analyticalsensitivity(n¬º2),andanalyticspeci

---

### Chunk 19/30
**Article:** Carboidratos IV (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.565

cose, evidenciando resist√™ncia perif√©rica √† insulina.
- A an√°lise isolada da glicemia de jejum pode levar a um diagn√≥stico incorreto de "sobrepeso saud√°vel", mascarando um problema metab√≥lico grave.
> **Sugest√µes da IA**
> O uso deste estudo de caso foi fundamental para traduzir a teoria em pr√°tica. Voc√™ demonstrou de forma excelente por que a glicemia de jejum isolada √© insuficiente. Ao apresentar os dados da curva, seria √∫til destacar verbalmente os valores de pico da insulina e da glicose e compar√°-los com os valores de refer√™ncia ideais, para que os alunos compreendam imediatamente a magnitude do problema. A sua cr√≠tica √† miopia do diagn√≥stico de "gordinho saud√°vel" foi muito pertinente e memor√°vel.
### 8. Estudo de Caso 2: Paciente Feminina com M√∫ltiplas Comorbidades e Hipoglicemia de Rebote
- Paciente: 71 anos, 1,54m, 87 kg, com m√∫ltiplas queixas (dores, alergias, depress√£o, hipertens√£o, etc.) e polifarm√°cia (incluindo estatina e Saxenda).

---

### Chunk 20/30
**Article:** Preparing Patients for Cosmetic Surgery and Aesthetic Procedures: Ensuring an Optimal Nutritional Status for Successful Results (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.564

Germani,A.;CapuzzoDolcetta,E.;Donini,L.M.;DelBalzo,V.TheNewModernMediterraneanDietItalianPyramid.Ann.Ig.2016,28,179‚Äì186.[PubMed]84.Wong,C.J.InvoluntaryWeightLoss.Med.Clin.NorthAm.2014,98,625‚Äì643.[CrossRef][PubMed]85.Cederholm,T.;Bosaeus,I.;Barazzoni,R.;Bauer,J.;VanGossum,A.;Klek,S.;Muscaritoli,M.;Nyulasi,I.;Ockenga,J.;Schneider,S.M.;etal.DiagnosticCriteriaforMalnutrition‚ÄîAnESPENConsensusStatement.Clin.Nutr.2015,34,335‚Äì340.[CrossRef][PubMed]86.Matory,W.E.J.;O‚ÄôSullivan,J.;Fudem,G.;Dunn,R.AbdominalSurgeryinPatientswithSevereMorbidObesity.Plast.Reconstr.Surg.1994,94,976‚Äì987.[CrossRef][PubMed]87.Gounden,V.;Vashisht,R.;Jialal,I.Hypoalbuminemia.InStatPearls;Anonymous;StatPearlsPublishingLLC:TreasureIsland,FL,USA,2022.88.Muscaritoli,M.;Arends,J.;Bachmann,P.;Baracos,V.;Barthelemy,N.;Bertz,H.;Bozzetti,F.;Hutterer,E.;Isenring,E.;Kaasa,S.;etal.ESPENPracticalGuideline:ClinicalNutritioninCancer.Clin.Nutr.2021,40,2898‚Äì2913.[CrossRef]89.Tuck,C.J.;Biesiekierski,J.R.;Schmid-Grendelmeier,P.

---

### Chunk 21/30
**Article:** Proteinuria (2023)
**Journal:** StatPearls Publishing
**Section:** abstract | **Similarity:** 0.564

Comprehensive clinical review of proteinuria covering definition, etiology, diagnosis, and management. Proteinuria serves as a marker of kidney damage assisting with diagnosis, prognosis, and therapy. Normal protein excretion is <150 mg/24 hours. Severity categories: nephritic range (150-3,500 mg/24h) and nephrotic range (>3,500 mg/24h). Urine dipstick provides semi-quantitative screening but has important limitations: false-positives with dehydration, alkaline urine, UTI; inability to detect positively charged proteins. UK CKD guidelines define significant proteinuria as UPCR >45 mg/mmol. Quantitative methods (spot UPCR preferred for convenience and reliability, or 24-hour urine collection for accuracy) are indicated when dipstick is positive or proteinuria >1 g/day is suspected. Early detection and quantification are crucial given associations with progressive renal disease and cardiovascular complications.

---

### Chunk 22/30
**Article:** Bioqu√≠mica Metab√≥lica nos Exerc√≠cios - Parte III (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.563

a n√£o consensual; dose pr√°tica 1 g 3x/dia.
### 13. Hipertrofia: inflama√ß√£o e modula√ß√£o
- Hipertrofia depende de sobrecarga mec√¢nica, microles√µes, grande processo inflamat√≥rio e aumento de s√≠ntese proteica.
- IL-6, ERO e lactato s√£o sinaliza√ß√µes √∫teis; evitar anti-inflamat√≥rios/crioterapia e excesso de antioxidantes imediatamente ap√≥s.
- Demandas proteicas aumentam com VO2, intensidade e frequ√™ncia.
### 14. D√©ficit energ√©tico cr√¥nico e sinais cl√≠nicos
- Indicativos: am√¥nia, ureia, √°cido √∫rico, transaminases, cortisol altos; queda de performance e de massa; desidrata√ß√£o; pior recupera√ß√£o.
- Sinais: queda de cabelo, unhas quebradi√ßas, imunidade baixa; bioimped√¢ncia mostra altera√ß√µes de √°gua; poss√≠vel aumento de TSH e queda de T3 por d√©ficit energ√©tico (pseudo-hipotireoidismo).
- Hipertrofia invi√°vel sob catabolismo salvo interven√ß√µes hormonais n√£o-mTOR com resultados limitados.
### 15.

---

### Chunk 23/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** methods | **Similarity:** 0.562

vision ofNephrology andHypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Shukugawara, Tama-Ku, Kawasaki, Kanagawa214-8525, Japan2 Division ofNephrology andHypertension, Department ofInternal Medicine, St. Marianna University School ofMedicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa216-8511, Japan3 Department ofNephrology, Chubu Rosai Hospital, 1-10-6, Komei-Cho, Minato-Ku, Nagoya, Aichi455-8530, Japan4 Division ofEndocrinology andMetabolism, Department ofMedicine, Georgetown University, 4000 Reservoir Rd NW, Washington, DC20007, USA

250
 Clinical and Experimental Nephrology (2025) 29:249‚Äì258
Common principles oftreatment ofhyponatremiaTreatment of hyponatremia is usually more challenging than that of other electrolyte disorders due to its complex-ity and varying treatment goals and methods recommended by diÔ¨Äerent guidelines [10, 12].

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.560

591.31.62.02.43.11.41.72.030‚Äì441.82.02.53.23.91.92.02.415‚Äì292.82.83.34.15.62.73.13.1<154.65.05.36.07.04.65.64.8105+1.42.03.04.15.41.21.62.290‚Äì104ref1.31.92.73.6ref1.31.660‚Äì891.01.41.72.43.21.11.31.745‚Äì591.41.72.22.83.81.41.61.930‚Äì442.02.32.83.74.61.61.72.015‚Äì293.23.13.55.06.51.82.12.1<156.16.46.47.38.23.22.82.9105+0.51.22.97.7251.21.72.790‚Äì104ref1.84.31243ref1.32.060‚Äì892.34.91027851.11.41.945‚Äì59131937892361.61.82.430‚Äì4450581152404632.22.53.115‚Äì2928330144379612533.63.54.1<1577010401618229725475.15.75.8105+1.01.62.43.75.51.11.31.790‚Äì104ref1.42.13.25.0ref1.21.560‚Äì891.62.23.14.36.71.01.21.445‚Äì593.54.05.16.99.01.21.31.530‚Äì445.65.96.88.6111.41.51.715‚Äì298.38.08.59.9101.91.82.0<158.5117.95.55.72.62.53.1105+1.41.72.12.12.30.91.41.990‚Äì104ref1.11.31.51.7ref1.31.960‚Äì891.01.11.31.51.81.01.31.845‚Äì591.31.31.51.72.11.51.72.1Urine albumin-creatinine rg/gm ,oitar eninitaerc-nimubla enirUg/gm ,oitaAll-cause mortality: 82 cohorts26 444 384 participants; 2 604 028 ev

---

### Chunk 25/30
**Article:** Mitoc√¥ndrias - Parte VI (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.559

etinol, ampliar por que medidas s√©ricas podem n√£o refletir o status corporal total (ex: distribui√ß√£o tecidual, homeostase, marcadores funcionais) aprofundaria o racioc√≠nio cl√≠nico.
### 3. Magn√©sio e √Åcido Alfa-Lipoico
- **Magn√©sio:** Um ter√ßo do magn√©sio celular est√° na mitoc√¥ndria, complexado com ATP; cofator da cadeia de transporte de el√©trons. Medi√ß√£o sangu√≠nea √© dispens√°vel segundo o instrutor. N√≠veis ideais, por estudos, >2,1, pois a defici√™ncia funcional precede a hipomagnesemia s√©rica.
- **√Åcido Alfa-Lipoico (ALA):** Cofator de enzimas mitocondriais cr√≠ticas; antioxidante amplamente estudado, atuante em meios hidrossol√∫veis e lipossol√∫veis.
> **Sugest√µes da IA**
> A distin√ß√£o entre refer√™ncia laboratorial e ‚Äúintervalo de sa√∫de‚Äù para magn√©sio √© crucial e bem colocada. Ao introduzir ALA como antioxidante chave, antecipe uma ou duas aplica√ß√µes cl√≠nicas (ex: neuropatia diab√©tica) para criar um gancho para a discuss√£o futura.
### 4.

---

### Chunk 26/30
**Article:** Bases Metab√≥licas das Doen√ßas Cr√¥nicas e Gerenciamento - Inflama√ß√£o 2 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.559

nto regular de PCR ultra-sens√≠vel em pacientes com sobrepeso, sinais de inflama√ß√£o ou risco oncol√≥gico/cardiovascular.
- [ ] 2. Diferenciar anemia por defici√™ncia de ferro de anemia da inflama√ß√£o usando painel: BCM/HCM/CHr, % eritr√≥citos hipocr√¥micos, transferrina, receptor de transferrina plasm√°tico, ferritina; considerar hepcidina em n√≠vel acad√™mico.
- [ ] 3. Ajustar plano alimentar conforme perfil: iniciar low carb para sobrepeso/inflama√ß√£o sem constipa√ß√£o; para mulheres constipadas, priorizar regula√ß√£o intestinal com incremento vegetal cuidadoso e poss√≠vel redu√ß√£o de carne vermelha.
- [ ] 4. Prescrever fibras n√£o fermentativas para constipa√ß√£o com gases: goma ac√°cia at√© 5 g/dia e polidextrose at√© 3 g/dia; avaliar resposta e adaptar.
- [ ] 5. Introduzir √¥mega 3 (EPA/DHA) com dose individualizada; garantir dieta antioxidante concomitante para evitar oxida√ß√£o e otimizar incorpora√ß√£o; evitar depender de ALA (linha√ßa/chia) como √∫nica fonte.
- [ ] 6.

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.559

g.ClinNephrol.1999;51:220‚Äì227.366.ParsonsMP,NewmanDJ,NewallRG,etal.Validationofapoint-of-care
assayfortheurinaryalbumin:creatinineratio.ClinChem.1999;45:414‚Äì417.367.PendersJ,FiersT,DelangheJR.Quantitativeevaluationofurinalysistest
strips.ClinChem.2002;48:2236‚Äì2241.368.PoulsenPL,MogensenCE.Clinicalevaluationofatestforimmediateand
quantitativedeterminationofurinaryalbumin-to-creatinineratio.Abrief
report.DiabetesCare.1998;21:97‚Äì98.369.PugiaMJ,LottJA,KajimaJ,etal.Screeningschoolchildrenfor
albuminuria,proteinuriaandoccultbloodwithdipsticks.ClinChemLabMed.1999;37:149‚Äì157.370.SakaiN,FuchigamiH,IshizukaT,etal.Relationshipbetweena
urineprotein-to-creatinineratioof150mg/gramcreatinineanddipstickgradeinthehealthcheckup:substantialnumberoffalse-
negativeresultsforchronickidneydisease.TokaiJExpClinMed.2019;44:118‚Äì123.371.SalinasM,L√≥pez-Garrig√≥sM,FloresE,etal.Urinaryalbuminstripassay
asascreeningtesttoreplacequantitativetechnologyincertain
conditions.ClinChemLabMed.2018;57:204‚Äì209.

---

### Chunk 28/30
**Article:** Research Progress and Treatment Status of Liver Cirrhosis with Hypoproteinemia (2022)
**Journal:** Evidence-Based Complementary and Alternative Medicine
**Section:** abstract | **Similarity:** 0.558

This review examines liver cirrhosis complicated by low protein levels (LCH), a condition affecting nutrient metabolism and causing serious health complications. The authors note that for every 10 g/L decrease in peripheral blood albumin, the risk of secondary liver disease complications will increase by 89%.

---

### Chunk 29/30
**Article:** Cardiologia VIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.558

isco:** Ferramentas como as tabelas de Framingham e MESA, embora matem√°ticas, s√£o imprecisas por n√£o considerarem uma vasta gama de vari√°veis metab√≥licas (ex: sono, hormonas, fun√ß√£o mitocondrial, insulina, hemoglobina glicada).
- **Gama GT (Gama-glutamil transferase):** Al√©m de ser um marcador de sa√∫de para rins, p√¢ncreas, f√≠gado e est√¥mago, a Gama GT (GGT) atua como um marcador de signific√¢ncia cl√≠nica para desfechos cardiovasculares. N√≠veis elevados podem indicar toxicidades cr√¥nicas (metais pesados, poluentes, defensivos agr√≠colas) e est√£o associados a maior risco cardiovascular e mortalidade geral. O objetivo terap√™utico √© manter o valor no quartil inferior da refer√™ncia. O uso de simbi√≥ticos pode ajudar a melhorar a fun√ß√£o hep√°tica.
- **Leuc√≥citos:** S√£o uma "marca individual" e sua an√°lise deve ser comparativa com o hist√≥rico do pr√≥prio paciente.

---

### Chunk 30/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIX (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.556

g/kg) e pr√°tica de exerc√≠cios de resist√™ncia para preservar massa muscular.
- [ ] 3. Todos os profissionais: Em doen√ßas cr√¥nicas sem causa org√¢nica clara ou com m√° resposta ao tratamento, investigar ativamente traumas de inf√¢ncia, estresse cr√¥nico e quest√µes emocionais n√£o resolvidas como poss√≠vel "causa primeira".
- [ ] 4. Terapeutas e psic√≥logos: Adotar "terapia de precis√£o", utilizando m√∫ltiplas ferramentas e combinando diferentes abordagens terap√™uticas para personalizar o tratamento e focar em resultados mensur√°veis, em vez de seguir uma √∫nica linha te√≥rica por longos per√≠odos.
- [ ] 5. Estudo pessoal: Pesquisar o conceito de "causa primeira" de Arist√≥teles para aprofundar a l√≥gica de buscar a origem dos problemas.
- [ ] 6. Estudo pessoal: Ler o livro de Bruce Lipton sobre a conex√£o entre mente e doen√ßas f√≠sicas.

---

## SOAP

> Data e Hora: 2025-11-17 16:33:53
> Paciente: 
> Diagn√≥stico:

## Hist√≥rico do Diagn√≥stico:
1. Hist√≥rico M√©dico: 
2.

---

